Alto Neuroscience, Inc. · NYSE (us_market)
Healthcare · Biotechnology · United States
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-03-16$24.29 RISE2026-03-30$19.98 PEAK2026-04-17$27.72 32d | -17.7% 14d | Missed | Missed | — | — | +38.7% 18d | Missed |
DROP2025-12-22$20.04 RISE2026-02-05$14.11 PEAK2026-04-17$27.72 116d | -29.6% 45d | Missed | Missed | — | — | +96.5% 71d | Missed |
DROP2025-03-06$3.95 RISE2025-06-30$2.20 PEAK2025-08-26$4.15 173d | -44.3% 116d | Missed | Missed | — | — | +88.6% 57d | Missed |
DROP2025-01-23$4.84 RISE2025-04-04$1.80 PEAK2025-05-23$3.03 120d | -62.8% 71d | Missed | Missed | — | — | +68.3% 49d | Missed |
DROP2024-10-22$14.53 RISE2024-12-18$3.64 PEAK2025-01-23$4.84 93d | -74.9% 57d | Missed | Missed | — | — | +33.0% 36d | Missed |
DROP2024-07-17$16.29 RISE2024-11-04$3.71 PEAK2024-11-11$4.84 117d | -77.2% 110d | Missed | Missed | — | — | +30.5% 7d | Missed |
DROP2024-07-17$16.29 RISE2024-08-12$8.22 PEAK2024-10-22$14.53 97d | -49.5% 26d | Missed | Missed | — | — | +76.8% 71d | Missed |
DROP2024-03-26$17.95 RISE2024-06-25$9.84 PEAK2024-07-17$16.29 113d | -45.2% 91d | Missed | Missed | — | — | +65.5% 22d | Missed |
DROP2024-02-05$21.80 RISE2024-02-22$13.00 PEAK2024-03-26$17.95 50d | -40.4% 17d | Missed | Missed | — | — | +38.1% 33d | Missed |
COPT Defense Properties serves defense and intelligence tenants near secure government hubs. Investors will be closely watching whether that niche can keep supporting growth while much of the office market remains under pressure.
Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE:ANRO) with a Outperform and lowers the price target from $38 to $36.
Alto Neuroscience, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit...
Wedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and raises the price target from $21 to $24.
NYSE: ANRO May 2026 1 for the Brain is Here. Precision Medicine OUR MISSION Redefining...
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.54) by 48.15 percent. This is a 42.86 percent decrease over losses of $(0.56) per share from
– Phase 2b clinical trial of ALTO-207 in treatment-resistant depression initiated –– New ALTO-101 analyses support significant effects on EEG markers of general cognition as well as a test...
Alto Neuroscience, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the...
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alto Neuroscience (NYSE:ANRO) with a Buy and maintains $50 price target.
Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the presentation of data from a randomized, single-blind,
— Randomized, placebo-controlled, Phase 2a trial demonstrated robust, statistically significant antidepressant effects of ALTO-207 and favorable tolerability; supporting development of ALTO-207 in...
— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies — — Trial design and MADRS primary endpoint aligned with FDA standards in depression, potentially supporting a single Phase 3 registrational pathway —
— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies —— Trial design and MADRS primary...
6,000,000 SharesCommon Stock Offered by the Selling StockholdersThis prospectus relates to the proposed resale from time to time of up to 6,000,000 shares, or the Shares, of our common stock, par value $0.0001 per share,
Alto Neuroscience deprioritized its lead asset Thursday, a treatment for cognitive impairment due to schizophrenia. The biotech stock tumbled.
Health care stocks declined late Thursday afternoon with the NYSE Health Care Index dropping 0.6% an
(Updates with the latest stock movement in the headline and the first paragraph.) Alto Neuroscien
Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE:ANRO) with a Outperform and lowers the price target from $41 to $38.
US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Quarry Inc. and Cocrystal Pharma Inc. shares increase.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ANRO | -19.53% | -2.71% | +12.75% | +677.91% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -22.50% | +3.00% | +16.20% | +665.22% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Citadel | multi-strat | 503.1K | $11.31M | 0.01% | Trimmed-68.7% | 2026-03-31 |
| TwoSigma | quant | 216.1K | $4.86M | 0.00% | Added+54.0% | 2026-03-31 |
| StateStreet | passive | 199.5K | $4.48M | 0.00% | Added+52.7% | 2026-03-31 |
| RenTech | quant | 103.5K | $2.33M | 0.00% | Added+6.3% | 2026-03-31 |
| Wellington | fundamental | 59.8K | $1.34M | 0.00% | Trimmed-13.4% | 2026-03-31 |
| DEShaw | quant | 45.3K | $1.02M | 0.00% | Trimmed-63.7% | 2026-03-31 |
| FidelityFMR | fundamental | 6.3K | $141.93K | 0.00% | Trimmed-0.9% | 2026-03-31 |
| TRowePrice | fundamental | 371.2K | $8.35K | 0.00% | Added+1128.0% | 2026-03-31 |